Chiesi explores the impact of climate change on people living with respiratory conditions in the series “The Climate and Us”

[ad_1] Chiesi Group proudly shares its contribution to the thought-provoking series “The Climate and Us”, presented by the Global Climate and Health Alliance and produced for them by BBC StoryWorks.…

Chiesi Global Rare Diseases Announces Multiple Presentations at SSIEM Annual Symposium 2023

[ad_1] – Total of six poster presentations analyze the effects of treatment with enzyme replacement therapies in Fabry disease and alpha-mannosidosis – – Company sponsoring symposium on advances in monitoring…

Chiesi Global Rare Diseases Announces Co-Development Agreement with Aliada Therapeutics to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

[ad_1] – Boston-based companies will collaborate on in vivo studies testing delivery modules harnessing transferrin and CD98 receptors – BOSTON, Aug. 15, 2023 /PRNewswire/ — Chiesi Global Rare Diseases, a…

Santhera Pharmaceuticals Closes Sale of Idebenone Business to Italy’s Chiesi Farmaceutici

[ad_1] Santhera Pharmaceuticals Closes Sale of Idebenone Business to Italy’s Chiesi Farmaceutici  Marketscreener.com [ad_2] Source link

Chiesi Global Rare Diseases Announces Approval of FERRIPROX™ MR Deferiprone Extended-Release Tablets in Canada

[ad_1] New formulation allows twice-daily dosing in patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate, or sickle cell disease or other anemias. BOSTON,…